nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—TNF—ankylosing spondylitis	0.912	1	CbGaD
Epinephrine—TNF—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.00224	0.0793	CbGpPWpGaD
Epinephrine—TNF—IL23-mediated signaling events—IL23R—ankylosing spondylitis	0.00148	0.0523	CbGpPWpGaD
Epinephrine—Skin necrosis—Methotrexate—ankylosing spondylitis	0.00132	0.0224	CcSEcCtD
Epinephrine—Rales—Methotrexate—ankylosing spondylitis	0.00113	0.0191	CcSEcCtD
Epinephrine—Nephropathy—Methotrexate—ankylosing spondylitis	0.000972	0.0164	CcSEcCtD
Epinephrine—Mydriasis—Prednisolone—ankylosing spondylitis	0.000955	0.0161	CcSEcCtD
Epinephrine—Necrosis—Methylprednisolone—ankylosing spondylitis	0.000891	0.015	CcSEcCtD
Epinephrine—Tingling sensation—Methylprednisolone—ankylosing spondylitis	0.00087	0.0147	CcSEcCtD
Epinephrine—Necrosis—Dexamethasone—ankylosing spondylitis	0.00081	0.0137	CcSEcCtD
Epinephrine—Necrosis—Betamethasone—ankylosing spondylitis	0.00081	0.0137	CcSEcCtD
Epinephrine—Tingling sensation—Dexamethasone—ankylosing spondylitis	0.000791	0.0134	CcSEcCtD
Epinephrine—Tingling sensation—Betamethasone—ankylosing spondylitis	0.000791	0.0134	CcSEcCtD
Epinephrine—TNF—IL27-mediated signaling events—IL17A—ankylosing spondylitis	0.000781	0.0276	CbGpPWpGaD
Epinephrine—Contusion—Betamethasone—ankylosing spondylitis	0.000729	0.0123	CcSEcCtD
Epinephrine—Contusion—Dexamethasone—ankylosing spondylitis	0.000729	0.0123	CcSEcCtD
Epinephrine—Extravasation—Betamethasone—ankylosing spondylitis	0.000729	0.0123	CcSEcCtD
Epinephrine—Extravasation—Dexamethasone—ankylosing spondylitis	0.000729	0.0123	CcSEcCtD
Epinephrine—TNF—IL27-mediated signaling events—IL12B—ankylosing spondylitis	0.000726	0.0257	CbGpPWpGaD
Epinephrine—PAH—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000712	0.0252	CbGpPWpGaD
Epinephrine—Necrosis—Prednisone—ankylosing spondylitis	0.000705	0.0119	CcSEcCtD
Epinephrine—Memory impairment—Prednisone—ankylosing spondylitis	0.000705	0.0119	CcSEcCtD
Epinephrine—TNF—Cytokines and Inflammatory Response—IL12B—ankylosing spondylitis	0.000705	0.0249	CbGpPWpGaD
Epinephrine—Pulmonary oedema—Prednisolone—ankylosing spondylitis	0.000678	0.0115	CcSEcCtD
Epinephrine—Skin exfoliation—Triamcinolone—ankylosing spondylitis	0.000669	0.0113	CcSEcCtD
Epinephrine—Skin exfoliation—Methylprednisolone—ankylosing spondylitis	0.000667	0.0113	CcSEcCtD
Epinephrine—Contusion—Prednisone—ankylosing spondylitis	0.000635	0.0107	CcSEcCtD
Epinephrine—Pulmonary oedema—Triamcinolone—ankylosing spondylitis	0.000624	0.0105	CcSEcCtD
Epinephrine—Pulmonary oedema—Methylprednisolone—ankylosing spondylitis	0.000622	0.0105	CcSEcCtD
Epinephrine—Skin exfoliation—Betamethasone—ankylosing spondylitis	0.000607	0.0103	CcSEcCtD
Epinephrine—Skin exfoliation—Dexamethasone—ankylosing spondylitis	0.000607	0.0103	CcSEcCtD
Epinephrine—TNF—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	0.000599	0.0212	CbGpPWpGaD
Epinephrine—Necrosis—Methotrexate—ankylosing spondylitis	0.00059	0.00996	CcSEcCtD
Epinephrine—TNF—IL23-mediated signaling events—IL17A—ankylosing spondylitis	0.000589	0.0208	CbGpPWpGaD
Epinephrine—TNF—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000574	0.0203	CbGpPWpGaD
Epinephrine—Pulmonary oedema—Dexamethasone—ankylosing spondylitis	0.000566	0.00956	CcSEcCtD
Epinephrine—Pulmonary oedema—Betamethasone—ankylosing spondylitis	0.000566	0.00956	CcSEcCtD
Epinephrine—TNF—TNF receptor signaling pathway —TNFRSF1B—ankylosing spondylitis	0.000555	0.0196	CbGpPWpGaD
Epinephrine—TNF—IL23-mediated signaling events—IL12B—ankylosing spondylitis	0.000548	0.0194	CbGpPWpGaD
Epinephrine—Extravasation—Methotrexate—ankylosing spondylitis	0.00053	0.00896	CcSEcCtD
Epinephrine—Skin exfoliation—Prednisone—ankylosing spondylitis	0.000529	0.00893	CcSEcCtD
Epinephrine—TNF—Cytokines and Inflammatory Response—IL1A—ankylosing spondylitis	0.000518	0.0183	CbGpPWpGaD
Epinephrine—TNF—Cytokines and Inflammatory Response—IL10—ankylosing spondylitis	0.000515	0.0182	CbGpPWpGaD
Epinephrine—TNF—Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.000504	0.0178	CbGpPWpGaD
Epinephrine—Psychotic disorder—Methylprednisolone—ankylosing spondylitis	0.000496	0.00837	CcSEcCtD
Epinephrine—Pulmonary oedema—Prednisone—ankylosing spondylitis	0.000493	0.00833	CcSEcCtD
Epinephrine—PAH—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000491	0.0174	CbGpPWpGaD
Epinephrine—Sweating increased—Prednisolone—ankylosing spondylitis	0.000466	0.00787	CcSEcCtD
Epinephrine—TNF—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.00046	0.0163	CbGpPWpGaD
Epinephrine—Psychotic disorder—Dexamethasone—ankylosing spondylitis	0.000451	0.00761	CcSEcCtD
Epinephrine—Psychotic disorder—Betamethasone—ankylosing spondylitis	0.000451	0.00761	CcSEcCtD
Epinephrine—Skin exfoliation—Methotrexate—ankylosing spondylitis	0.000442	0.00746	CcSEcCtD
Epinephrine—Sweating increased—Triamcinolone—ankylosing spondylitis	0.000428	0.00723	CcSEcCtD
Epinephrine—Sweating increased—Methylprednisolone—ankylosing spondylitis	0.000427	0.00722	CcSEcCtD
Epinephrine—Acute coronary syndrome—Prednisolone—ankylosing spondylitis	0.00042	0.0071	CcSEcCtD
Epinephrine—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.00042	0.0071	CcSEcCtD
Epinephrine—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.00042	0.0071	CcSEcCtD
Epinephrine—Myocardial infarction—Prednisolone—ankylosing spondylitis	0.000418	0.00706	CcSEcCtD
Epinephrine—Pulmonary oedema—Methotrexate—ankylosing spondylitis	0.000412	0.00696	CcSEcCtD
Epinephrine—Psychotic disorder—Prednisone—ankylosing spondylitis	0.000393	0.00663	CcSEcCtD
Epinephrine—Sweating increased—Betamethasone—ankylosing spondylitis	0.000389	0.00656	CcSEcCtD
Epinephrine—Sweating increased—Dexamethasone—ankylosing spondylitis	0.000389	0.00656	CcSEcCtD
Epinephrine—Acute coronary syndrome—Triamcinolone—ankylosing spondylitis	0.000386	0.00653	CcSEcCtD
Epinephrine—Acute coronary syndrome—Methylprednisolone—ankylosing spondylitis	0.000386	0.00651	CcSEcCtD
Epinephrine—Haemoglobin—Prednisolone—ankylosing spondylitis	0.000385	0.0065	CcSEcCtD
Epinephrine—Myocardial infarction—Triamcinolone—ankylosing spondylitis	0.000384	0.00649	CcSEcCtD
Epinephrine—Myocardial infarction—Methylprednisolone—ankylosing spondylitis	0.000383	0.00648	CcSEcCtD
Epinephrine—Haemorrhage—Prednisolone—ankylosing spondylitis	0.000383	0.00646	CcSEcCtD
Epinephrine—Sweating—Methylprednisolone—ankylosing spondylitis	0.000375	0.00633	CcSEcCtD
Epinephrine—Hypokalaemia—Prednisone—ankylosing spondylitis	0.000366	0.00618	CcSEcCtD
Epinephrine—TNF—FAS pathway and Stress induction of HSP regulation—IL1A—ankylosing spondylitis	0.000364	0.0129	CbGpPWpGaD
Epinephrine—Hyperglycaemia—Betamethasone—ankylosing spondylitis	0.00036	0.00608	CcSEcCtD
Epinephrine—Hyperglycaemia—Dexamethasone—ankylosing spondylitis	0.00036	0.00608	CcSEcCtD
Epinephrine—PAH—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000354	0.0125	CbGpPWpGaD
Epinephrine—Haemoglobin—Triamcinolone—ankylosing spondylitis	0.000354	0.00597	CcSEcCtD
Epinephrine—Haemoglobin—Methylprednisolone—ankylosing spondylitis	0.000353	0.00596	CcSEcCtD
Epinephrine—TNF—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000353	0.0125	CbGpPWpGaD
Epinephrine—Haemorrhage—Triamcinolone—ankylosing spondylitis	0.000352	0.00594	CcSEcCtD
Epinephrine—PAH—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000352	0.0124	CbGpPWpGaD
Epinephrine—Haemorrhage—Methylprednisolone—ankylosing spondylitis	0.000351	0.00593	CcSEcCtD
Epinephrine—TNF—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000351	0.0124	CbGpPWpGaD
Epinephrine—Acute coronary syndrome—Dexamethasone—ankylosing spondylitis	0.000351	0.00592	CcSEcCtD
Epinephrine—Acute coronary syndrome—Betamethasone—ankylosing spondylitis	0.000351	0.00592	CcSEcCtD
Epinephrine—Hallucination—Methylprednisolone—ankylosing spondylitis	0.000349	0.0059	CcSEcCtD
Epinephrine—Myocardial infarction—Dexamethasone—ankylosing spondylitis	0.000349	0.00589	CcSEcCtD
Epinephrine—Myocardial infarction—Betamethasone—ankylosing spondylitis	0.000349	0.00589	CcSEcCtD
Epinephrine—TNF—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.000343	0.0121	CbGpPWpGaD
Epinephrine—Cerebrovascular accident—Methotrexate—ankylosing spondylitis	0.000343	0.00579	CcSEcCtD
Epinephrine—Arrhythmia—Prednisolone—ankylosing spondylitis	0.000342	0.00577	CcSEcCtD
Epinephrine—Sweating increased—Prednisone—ankylosing spondylitis	0.000338	0.00572	CcSEcCtD
Epinephrine—Erythema—Prednisolone—ankylosing spondylitis	0.000333	0.00563	CcSEcCtD
Epinephrine—ADRBK1—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000326	0.0115	CbGpPWpGaD
Epinephrine—ADRB3—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.000323	0.0114	CbGpPWpGaD
Epinephrine—TNF—Allograft Rejection—IL17A—ankylosing spondylitis	0.000321	0.0113	CbGpPWpGaD
Epinephrine—Haemoglobin—Dexamethasone—ankylosing spondylitis	0.000321	0.00542	CcSEcCtD
Epinephrine—Haemoglobin—Betamethasone—ankylosing spondylitis	0.000321	0.00542	CcSEcCtD
Epinephrine—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000319	0.00539	CcSEcCtD
Epinephrine—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000319	0.00539	CcSEcCtD
Epinephrine—TNF—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.000319	0.0113	CbGpPWpGaD
Epinephrine—Hallucination—Betamethasone—ankylosing spondylitis	0.000318	0.00537	CcSEcCtD
Epinephrine—Hallucination—Dexamethasone—ankylosing spondylitis	0.000318	0.00537	CcSEcCtD
Epinephrine—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000315	0.0111	CbGpPWpGaD
Epinephrine—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.000314	0.00531	CcSEcCtD
Epinephrine—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.000314	0.0053	CcSEcCtD
Epinephrine—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.000313	0.00529	CcSEcCtD
Epinephrine—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000308	0.0052	CcSEcCtD
Epinephrine—Erythema—Triamcinolone—ankylosing spondylitis	0.000306	0.00517	CcSEcCtD
Epinephrine—Erythema—Methylprednisolone—ankylosing spondylitis	0.000306	0.00516	CcSEcCtD
Epinephrine—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.000305	0.00516	CcSEcCtD
Epinephrine—Myocardial infarction—Prednisone—ankylosing spondylitis	0.000304	0.00513	CcSEcCtD
Epinephrine—TNF—Allograft Rejection—IL12B—ankylosing spondylitis	0.000298	0.0105	CbGpPWpGaD
Epinephrine—Hypertension—Prednisolone—ankylosing spondylitis	0.000288	0.00486	CcSEcCtD
Epinephrine—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000285	0.00482	CcSEcCtD
Epinephrine—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000285	0.00482	CcSEcCtD
Epinephrine—Haemoglobin—Prednisone—ankylosing spondylitis	0.000279	0.00472	CcSEcCtD
Epinephrine—Haemorrhage—Prednisone—ankylosing spondylitis	0.000278	0.0047	CcSEcCtD
Epinephrine—Erythema—Betamethasone—ankylosing spondylitis	0.000278	0.0047	CcSEcCtD
Epinephrine—Erythema—Dexamethasone—ankylosing spondylitis	0.000278	0.0047	CcSEcCtD
Epinephrine—Hallucination—Prednisone—ankylosing spondylitis	0.000277	0.00467	CcSEcCtD
Epinephrine—SLC22A5—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000266	0.0094	CbGpPWpGaD
Epinephrine—Tachycardia—Prednisolone—ankylosing spondylitis	0.000265	0.00448	CcSEcCtD
Epinephrine—Hypertension—Triamcinolone—ankylosing spondylitis	0.000264	0.00447	CcSEcCtD
Epinephrine—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000264	0.00446	CcSEcCtD
Epinephrine—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000263	0.00444	CcSEcCtD
Epinephrine—TNF—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.00026	0.0092	CbGpPWpGaD
Epinephrine—Drowsiness—Methotrexate—ankylosing spondylitis	0.000259	0.00437	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000258	0.00437	CcSEcCtD
Epinephrine—Flushing—Prednisone—ankylosing spondylitis	0.000258	0.00436	CcSEcCtD
Epinephrine—TNF—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000256	0.00906	CbGpPWpGaD
Epinephrine—Renal failure—Methotrexate—ankylosing spondylitis	0.000254	0.0043	CcSEcCtD
Epinephrine—Arrhythmia—Prednisone—ankylosing spondylitis	0.000248	0.0042	CcSEcCtD
Epinephrine—Sweating—Methotrexate—ankylosing spondylitis	0.000248	0.00419	CcSEcCtD
Epinephrine—Insomnia—Prednisolone—ankylosing spondylitis	0.000246	0.00415	CcSEcCtD
Epinephrine—PAH—Disease—ANTXR2—ankylosing spondylitis	0.000245	0.00868	CbGpPWpGaD
Epinephrine—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000245	0.00413	CcSEcCtD
Epinephrine—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000244	0.00412	CcSEcCtD
Epinephrine—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000244	0.00412	CcSEcCtD
Epinephrine—Mental disorder—Prednisone—ankylosing spondylitis	0.000244	0.00412	CcSEcCtD
Epinephrine—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000243	0.00411	CcSEcCtD
Epinephrine—TNF—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000243	0.0086	CbGpPWpGaD
Epinephrine—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000242	0.00409	CcSEcCtD
Epinephrine—Erythema—Prednisone—ankylosing spondylitis	0.000242	0.00409	CcSEcCtD
Epinephrine—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000242	0.00408	CcSEcCtD
Epinephrine—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000241	0.00407	CcSEcCtD
Epinephrine—Hypertension—Betamethasone—ankylosing spondylitis	0.00024	0.00405	CcSEcCtD
Epinephrine—Hypertension—Dexamethasone—ankylosing spondylitis	0.00024	0.00405	CcSEcCtD
Epinephrine—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000234	0.00395	CcSEcCtD
Epinephrine—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000232	0.00393	CcSEcCtD
Epinephrine—Insomnia—Triamcinolone—ankylosing spondylitis	0.000226	0.00382	CcSEcCtD
Epinephrine—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000226	0.00381	CcSEcCtD
Epinephrine—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000224	0.00379	CcSEcCtD
Epinephrine—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000224	0.00378	CcSEcCtD
Epinephrine—ADRBK1—Immune System—KIR3DL1—ankylosing spondylitis	0.000224	0.0079	CbGpPWpGaD
Epinephrine—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000222	0.00376	CcSEcCtD
Epinephrine—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000222	0.00376	CcSEcCtD
Epinephrine—Agitation—Prednisone—ankylosing spondylitis	0.000222	0.00376	CcSEcCtD
Epinephrine—TNF—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000222	0.00785	CbGpPWpGaD
Epinephrine—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000221	0.00374	CcSEcCtD
Epinephrine—Tachycardia—Betamethasone—ankylosing spondylitis	0.000221	0.00374	CcSEcCtD
Epinephrine—TNF—Allograft Rejection—IL1A—ankylosing spondylitis	0.00022	0.00776	CbGpPWpGaD
Epinephrine—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000219	0.0037	CcSEcCtD
Epinephrine—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000219	0.0037	CcSEcCtD
Epinephrine—TNF—Allograft Rejection—IL10—ankylosing spondylitis	0.000218	0.00771	CbGpPWpGaD
Epinephrine—TNF—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000218	0.00771	CbGpPWpGaD
Epinephrine—TNF—Folate Metabolism—CRP—ankylosing spondylitis	0.000212	0.00749	CbGpPWpGaD
Epinephrine—Hypertension—Prednisone—ankylosing spondylitis	0.000209	0.00353	CcSEcCtD
Epinephrine—TNF—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000208	0.00734	CbGpPWpGaD
Epinephrine—Insomnia—Dexamethasone—ankylosing spondylitis	0.000205	0.00347	CcSEcCtD
Epinephrine—Insomnia—Betamethasone—ankylosing spondylitis	0.000205	0.00347	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000205	0.00346	CcSEcCtD
Epinephrine—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000204	0.00344	CcSEcCtD
Epinephrine—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000204	0.00344	CcSEcCtD
Epinephrine—Mental disorder—Methotrexate—ankylosing spondylitis	0.000204	0.00344	CcSEcCtD
Epinephrine—Erythema—Methotrexate—ankylosing spondylitis	0.000202	0.00342	CcSEcCtD
Epinephrine—ADRBK1—Innate Immune System—CARD9—ankylosing spondylitis	0.000202	0.00712	CbGpPWpGaD
Epinephrine—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000196	0.00331	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000196	0.00331	CcSEcCtD
Epinephrine—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000194	0.00327	CcSEcCtD
Epinephrine—Tachycardia—Prednisone—ankylosing spondylitis	0.000193	0.00326	CcSEcCtD
Epinephrine—ADRBK1—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000193	0.00681	CbGpPWpGaD
Epinephrine—TNF—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000192	0.0068	CbGpPWpGaD
Epinephrine—Skin disorder—Prednisone—ankylosing spondylitis	0.000192	0.00324	CcSEcCtD
Epinephrine—ADRB1—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.000192	0.00677	CbGpPWpGaD
Epinephrine—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000191	0.00323	CcSEcCtD
Epinephrine—TNF—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.00019	0.00671	CbGpPWpGaD
Epinephrine—ADRB2—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.000188	0.00663	CbGpPWpGaD
Epinephrine—ADRBK1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000184	0.00652	CbGpPWpGaD
Epinephrine—Dizziness—Prednisolone—ankylosing spondylitis	0.00018	0.00304	CcSEcCtD
Epinephrine—ADRB3—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00018	0.00635	CbGpPWpGaD
Epinephrine—Insomnia—Prednisone—ankylosing spondylitis	0.000179	0.00302	CcSEcCtD
Epinephrine—Paraesthesia—Prednisone—ankylosing spondylitis	0.000177	0.003	CcSEcCtD
Epinephrine—TNF—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000177	0.00625	CbGpPWpGaD
Epinephrine—Chest pain—Methotrexate—ankylosing spondylitis	0.000172	0.00291	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000171	0.00289	CcSEcCtD
Epinephrine—TNF—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000168	0.00595	CbGpPWpGaD
Epinephrine—SLC22A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000167	0.00591	CbGpPWpGaD
Epinephrine—Dizziness—Triamcinolone—ankylosing spondylitis	0.000165	0.00279	CcSEcCtD
Epinephrine—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000165	0.00279	CcSEcCtD
Epinephrine—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000162	0.00274	CcSEcCtD
Epinephrine—Nausea—Prednisolone—ankylosing spondylitis	0.000161	0.00273	CcSEcCtD
Epinephrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000161	0.00569	CbGpPWpGaD
Epinephrine—Skin disorder—Methotrexate—ankylosing spondylitis	0.00016	0.00271	CcSEcCtD
Epinephrine—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.00016	0.0027	CcSEcCtD
Epinephrine—TNF—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000159	0.00563	CbGpPWpGaD
Epinephrine—Vomiting—Triamcinolone—ankylosing spondylitis	0.000159	0.00269	CcSEcCtD
Epinephrine—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000159	0.00268	CcSEcCtD
Epinephrine—ADRBK1—Disease—ANTXR2—ankylosing spondylitis	0.000156	0.00553	CbGpPWpGaD
Epinephrine—SLC22A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000156	0.00551	CbGpPWpGaD
Epinephrine—ADRB3—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000154	0.00544	CbGpPWpGaD
Epinephrine—Dizziness—Betamethasone—ankylosing spondylitis	0.00015	0.00253	CcSEcCtD
Epinephrine—Dizziness—Dexamethasone—ankylosing spondylitis	0.00015	0.00253	CcSEcCtD
Epinephrine—Insomnia—Methotrexate—ankylosing spondylitis	0.000149	0.00252	CcSEcCtD
Epinephrine—Nausea—Triamcinolone—ankylosing spondylitis	0.000148	0.00251	CcSEcCtD
Epinephrine—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000148	0.0025	CcSEcCtD
Epinephrine—Nausea—Methylprednisolone—ankylosing spondylitis	0.000148	0.0025	CcSEcCtD
Epinephrine—Somnolence—Methotrexate—ankylosing spondylitis	0.000147	0.00248	CcSEcCtD
Epinephrine—PAH—Disease—B3GNT2—ankylosing spondylitis	0.000145	0.00511	CbGpPWpGaD
Epinephrine—Vomiting—Dexamethasone—ankylosing spondylitis	0.000144	0.00244	CcSEcCtD
Epinephrine—Vomiting—Betamethasone—ankylosing spondylitis	0.000144	0.00244	CcSEcCtD
Epinephrine—TNF—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000143	0.00507	CbGpPWpGaD
Epinephrine—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000143	0.00241	CcSEcCtD
Epinephrine—ADRBK1—Immune System—IL1R2—ankylosing spondylitis	0.000135	0.00479	CbGpPWpGaD
Epinephrine—Nausea—Betamethasone—ankylosing spondylitis	0.000135	0.00228	CcSEcCtD
Epinephrine—Nausea—Dexamethasone—ankylosing spondylitis	0.000135	0.00228	CcSEcCtD
Epinephrine—PAH—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000134	0.00473	CbGpPWpGaD
Epinephrine—Dizziness—Prednisone—ankylosing spondylitis	0.000131	0.00221	CcSEcCtD
Epinephrine—ADRBK1—Immune System—ERAP1—ankylosing spondylitis	0.000128	0.00454	CbGpPWpGaD
Epinephrine—TNF—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000128	0.00451	CbGpPWpGaD
Epinephrine—TNF—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000127	0.0045	CbGpPWpGaD
Epinephrine—TNF—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000127	0.00448	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000127	0.00447	CbGpPWpGaD
Epinephrine—Vomiting—Prednisone—ankylosing spondylitis	0.000126	0.00212	CcSEcCtD
Epinephrine—PAH—Metabolism—B3GNT2—ankylosing spondylitis	0.000121	0.00428	CbGpPWpGaD
Epinephrine—TNF—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.00012	0.00424	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—CARD9—ankylosing spondylitis	0.000117	0.00415	CbGpPWpGaD
Epinephrine—Nausea—Prednisone—ankylosing spondylitis	0.000117	0.00198	CcSEcCtD
Epinephrine—ADRB3—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000117	0.00414	CbGpPWpGaD
Epinephrine—ADRA1D—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000117	0.00414	CbGpPWpGaD
Epinephrine—TNF—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000112	0.00396	CbGpPWpGaD
Epinephrine—Dizziness—Methotrexate—ankylosing spondylitis	0.000109	0.00184	CcSEcCtD
Epinephrine—ADRB1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000107	0.00377	CbGpPWpGaD
Epinephrine—ADRA2B—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000106	0.00374	CbGpPWpGaD
Epinephrine—Vomiting—Methotrexate—ankylosing spondylitis	0.000105	0.00177	CcSEcCtD
Epinephrine—ADRB2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000104	0.00369	CbGpPWpGaD
Epinephrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.0001	0.00354	CbGpPWpGaD
Epinephrine—ADRA2C—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	9.87e-05	0.00349	CbGpPWpGaD
Epinephrine—Nausea—Methotrexate—ankylosing spondylitis	9.81e-05	0.00166	CcSEcCtD
Epinephrine—ADRA1B—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	9.72e-05	0.00343	CbGpPWpGaD
Epinephrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	9.64e-05	0.00341	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—B3GNT2—ankylosing spondylitis	9.22e-05	0.00326	CbGpPWpGaD
Epinephrine—ADRB1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	9.14e-05	0.00323	CbGpPWpGaD
Epinephrine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	9.06e-05	0.0032	CbGpPWpGaD
Epinephrine—ADRB2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	8.94e-05	0.00316	CbGpPWpGaD
Epinephrine—ADRA1A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	8.63e-05	0.00305	CbGpPWpGaD
Epinephrine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	8.46e-05	0.00299	CbGpPWpGaD
Epinephrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	8.33e-05	0.00294	CbGpPWpGaD
Epinephrine—ADRBK1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	8.25e-05	0.00292	CbGpPWpGaD
Epinephrine—ADRA2A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	8.02e-05	0.00283	CbGpPWpGaD
Epinephrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	8e-05	0.00283	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR ligand binding—PTGER4—ankylosing spondylitis	7.64e-05	0.0027	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—PTGER4—ankylosing spondylitis	7.5e-05	0.00265	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—HLA-B—ankylosing spondylitis	7.49e-05	0.00265	CbGpPWpGaD
Epinephrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	7.39e-05	0.00261	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—HLA-C—ankylosing spondylitis	7.37e-05	0.00261	CbGpPWpGaD
Epinephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	7.11e-05	0.00251	CbGpPWpGaD
Epinephrine—ADRB1—GPCR ligand binding—PTGER4—ankylosing spondylitis	6.96e-05	0.00246	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR ligand binding—PTGER4—ankylosing spondylitis	6.9e-05	0.00244	CbGpPWpGaD
Epinephrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	6.87e-05	0.00243	CbGpPWpGaD
Epinephrine—ADRB2—GPCR ligand binding—PTGER4—ankylosing spondylitis	6.81e-05	0.00241	CbGpPWpGaD
Epinephrine—ADRB3—GPCR downstream signaling—PTGER4—ankylosing spondylitis	6.63e-05	0.00234	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—CRP—ankylosing spondylitis	6.62e-05	0.00234	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR ligand binding—PTGER4—ankylosing spondylitis	6.44e-05	0.00228	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—IL1RN—ankylosing spondylitis	6.41e-05	0.00226	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—TLR4—ankylosing spondylitis	6.34e-05	0.00224	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR ligand binding—PTGER4—ankylosing spondylitis	6.34e-05	0.00224	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—PTGER4—ankylosing spondylitis	6.02e-05	0.00213	CbGpPWpGaD
Epinephrine—PAH—Disease—HLA-A—ankylosing spondylitis	5.85e-05	0.00207	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR ligand binding—PTGER4—ankylosing spondylitis	5.63e-05	0.00199	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—CD79A—ankylosing spondylitis	5.62e-05	0.00199	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—MMP3—ankylosing spondylitis	5.34e-05	0.00189	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR ligand binding—PTGER4—ankylosing spondylitis	5.23e-05	0.00185	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—IL1A—ankylosing spondylitis	4.61e-05	0.00163	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—CD40LG—ankylosing spondylitis	4.58e-05	0.00162	CbGpPWpGaD
Epinephrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	4.48e-05	0.00158	CbGpPWpGaD
Epinephrine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	4.48e-05	0.00158	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—PTGER4—ankylosing spondylitis	4.43e-05	0.00156	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—HLA-B—ankylosing spondylitis	4.36e-05	0.00154	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR downstream signaling—PTGER4—ankylosing spondylitis	4.32e-05	0.00153	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—MMP3—ankylosing spondylitis	4.28e-05	0.00151	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—HLA-A—ankylosing spondylitis	4.04e-05	0.00143	CbGpPWpGaD
Epinephrine—ADRB1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	3.93e-05	0.00139	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—PTGER4—ankylosing spondylitis	3.92e-05	0.00139	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR downstream signaling—PTGER4—ankylosing spondylitis	3.9e-05	0.00138	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—CRP—ankylosing spondylitis	3.85e-05	0.00136	CbGpPWpGaD
Epinephrine—ADRB2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	3.85e-05	0.00136	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—HLA-A—ankylosing spondylitis	3.73e-05	0.00132	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—TLR4—ankylosing spondylitis	3.7e-05	0.00131	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR downstream signaling—PTGER4—ankylosing spondylitis	3.64e-05	0.00129	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—PTGER4—ankylosing spondylitis	3.58e-05	0.00127	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—PTGER4—ankylosing spondylitis	3.57e-05	0.00126	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—PTGER4—ankylosing spondylitis	3.55e-05	0.00126	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—PTGER4—ankylosing spondylitis	3.54e-05	0.00125	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—B3GNT2—ankylosing spondylitis	3.5e-05	0.00124	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—PTGER4—ankylosing spondylitis	3.49e-05	0.00123	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—B3GNT2—ankylosing spondylitis	3.4e-05	0.0012	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—PTGER4—ankylosing spondylitis	3.31e-05	0.00117	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—B3GNT2—ankylosing spondylitis	3.26e-05	0.00115	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—PTGER4—ankylosing spondylitis	3.25e-05	0.00115	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	3.18e-05	0.00112	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—MMP3—ankylosing spondylitis	3.15e-05	0.00111	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	2.96e-05	0.00104	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—PTGER4—ankylosing spondylitis	2.89e-05	0.00102	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—MMP3—ankylosing spondylitis	2.79e-05	0.000986	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—B3GNT2—ankylosing spondylitis	2.77e-05	0.000977	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—PTGER4—ankylosing spondylitis	2.69e-05	0.000949	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—MMP3—ankylosing spondylitis	2.54e-05	0.000899	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—MMP3—ankylosing spondylitis	2.53e-05	0.000894	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—MMP3—ankylosing spondylitis	2.52e-05	0.00089	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—MMP3—ankylosing spondylitis	2.49e-05	0.000879	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—MMP3—ankylosing spondylitis	2.35e-05	0.000832	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—MMP3—ankylosing spondylitis	2.32e-05	0.000819	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PTGER4—ankylosing spondylitis	2.32e-05	0.000818	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PTGER4—ankylosing spondylitis	2.11e-05	0.000746	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PTGER4—ankylosing spondylitis	2.09e-05	0.000739	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PTGER4—ankylosing spondylitis	2.06e-05	0.000729	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—MMP3—ankylosing spondylitis	2.06e-05	0.000727	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PTGER4—ankylosing spondylitis	1.95e-05	0.00069	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PTGER4—ankylosing spondylitis	1.92e-05	0.000679	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—MMP3—ankylosing spondylitis	1.91e-05	0.000676	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	1.79e-05	0.000631	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PTGER4—ankylosing spondylitis	1.71e-05	0.000603	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MMP3—ankylosing spondylitis	1.65e-05	0.000583	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PTGER4—ankylosing spondylitis	1.59e-05	0.000561	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	1.53e-05	0.00054	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MMP3—ankylosing spondylitis	1.5e-05	0.000531	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MMP3—ankylosing spondylitis	1.49e-05	0.000526	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MMP3—ankylosing spondylitis	1.47e-05	0.000519	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MMP3—ankylosing spondylitis	1.39e-05	0.000491	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MMP3—ankylosing spondylitis	1.37e-05	0.000484	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MMP3—ankylosing spondylitis	1.22e-05	0.00043	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	1.18e-05	0.000416	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MMP3—ankylosing spondylitis	1.13e-05	0.000399	CbGpPWpGaD
